A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report.
NRAS mutation
PD-1 inhibitor
TERT promoter mutations
TP53 mutations
anaplastic thyroid carcinoma
anti-angiogenesis drug
next-generation sequencing
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
02
2021
accepted:
06
04
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
29
4
2021
Statut:
epublish
Résumé
Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive fatal tumor. Most ATC patients using traditional surgery or radio-chemotherapy have poor prognosis and experience recurrence in a very short time. There is no optimal therapy for ATC, and the median survival time is about 5 months. We report a 67-year-old ATC patient, who experienced rapid local recurrence after radical thyroidectomy. The resected tumor tissue was sent for immunohistochemistry analysis and targeted next-generation sequencing. The results indicated high PD-L1 expression, a tumor mutation burden of 0.48 muts/Mb, microsatellite stable, and somatic mutations of
Identifiants
pubmed: 33907417
doi: 10.2147/OTT.S305196
pii: 305196
pmc: PMC8068508
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2741-2746Informations de copyright
© 2021 Gui et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Eur J Surg. 2000 Jan;166(1):34-8
pubmed: 10688214
Minerva Chir. 2013 Jun;68(3):321-8
pubmed: 23774098
Semin Cancer Biol. 2020 Apr;61:23-29
pubmed: 31991166
AJR Am J Roentgenol. 2001 Aug;177(2):474
pubmed: 11461895
Head Neck. 2016 Apr;38 Suppl 1:E2083-90
pubmed: 26894506
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
J Clin Endocrinol Metab. 2016 Jul;101(7):2863-73
pubmed: 27045886
Drugs. 2019 Feb;79(3):341-346
pubmed: 30742278
Thyroid. 2020 Feb;30(2):343-344
pubmed: 31892283
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
PLoS One. 2019 Feb 27;14(2):e0212513
pubmed: 30811474
Onco Targets Ther. 2017 Aug 08;10:3941-3947
pubmed: 28860801
Cancer. 2005 Apr 1;103(7):1330-5
pubmed: 15739211
Cancer J. 2018 Jul/Aug;24(4):193-204
pubmed: 30119083
JCO Precis Oncol. 2019;3:
pubmed: 31192313
J Hematol Oncol. 2016 Oct 4;9(1):105
pubmed: 27716285
Thyroid. 2018 Mar;28(3):349-361
pubmed: 29455638
Front Oncol. 2017 Mar 01;7:25
pubmed: 28299283
Clin Ter. 2013;164(4):e343-6
pubmed: 24045534
Thyroid. 2018 Nov;28(11):1455-1461
pubmed: 30142994
J Immunother Cancer. 2018 Jul 11;6(1):68
pubmed: 29996921
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Endocr Relat Cancer. 2019 Jan 1;26(1):153-164
pubmed: 30139768
Oncologist. 2017 Oct;22(10):1149-1151
pubmed: 28778959
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Int J Surg. 2017 May;41 Suppl 1:S13-S20
pubmed: 28506407